Picard Medical, Inc. · AMEX:PMI
Picard Medical — IPO Roadshow (July 2025)
24 slides from Picard Medical's IPO roadshow presentation, Jul 30, 2025
Slide 1: Explanatory note
• Explanatory note: This Free Writing Prospectus was initially filed on the Electronic Data Gathering, Analysis, and Retrieval (EDGAR) system of the Securities and Exchange Commission on July 18, 2025. Solely for the purpose of correcting a scrivener’s error and updating certain limited information
Slide 2: Picard Medical Inc. Issuer Free Writing Prospectus
SynCardia's products are approved for sale in the U.S. and Canada only. © SynCardia Systems, LLC. All rights reserved | www. SynCardia .com Picard Medical Inc. Proposed NYSE American Ticker: PMI Filed pursuant to Rule 433 of the Securities Act of 1933, as amended. Issuer Free Writing Prospectus date
Slide 3: Forward-looking statements
This Presentation contains statements that are “forward - looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 . Forward - looking statements include all statements that do not relate solely to historical or current facts and can generally be identified by t
Slide 4: Disclaimer
Neither the Company nor any of its subsidiaries, affiliates, representatives or advisors assumes any responsibility for or makes any representation or warranty (express or implied) as to, the reasonableness, completeness, accuracy or reliability of the estimates and information contained herein, whi
Slide 5: Our Mission
Our Mission To pioneer the future of heart replacement by providing the world’s first Total Artificial Heart and developing the next - generation system as an alternative to transplantation SynCardia's products are approved for sale in the U . S . and Canada only . SynCarida Systems, LLC is a wholly
Slide 6: SynCardia At-a-Glance
SynCardia At - a - Glance SynCardia's products are approved for sale in the U.S. and Canada only. SynCarida Systems, LLC is a wholly owned subsidiary of Picard Medical Inc. © SynCardia Systems, LLC. All rights reserved. 5 Market Leader: Global innovator in total artificial heart technology and a who
Slide 7: The Initial Public Offering Summary
The Initial Public Offering Summary Picard Medical, Inc. Issuer NYSE American Proposed Exchange PMI Proposed Ticker August 2025 Proposed IPO date $3.50 to $4.50 Proposed Price Range 68,074,145 Outstanding Shares prior to Offer Common Stock Share Type 4,250,000 1 Offering Shares 72,324,145 1 Outstand
Slide 8: Use of Proceeds
Use of Proceeds 1 Purpose Amount Category • R&D for our fully implantable system including early feasibility animal trials and additional design and engineering activities ~$2.96M R&D, Product Development • Expand sales, marketing, and distribution capabilities & support inventory growth • Broaden i
Slide 9: Driving Scalable Growth with an Experienced, Results-Focused Team
Driving Scalable Growth with an Experienced, Results - Focused Team CEO Patrick NJ Schnegelsberg COO Matt Schuster CFO Bernard Skaggs Patrick has 25 years of executive leadership in the medical device sector and was appointed CEO in July 2023. He served as CEO of Syntach AB (2022 – 2023) and as COO
Slide 10: Years of Leadership: From First FDA Approval to Future Innovation
20 Years of Leadership: From First FDA Approval to Future Innovation - Proven Legacy in Total Artificial Hearts Patient Hospitalized Patient Mobile in Hospital Patient Mobile in Home Children & Small Adults Alternative to Heart Transplant 2012 FDA approves Companion C2 Driver 2014 FDA approves Freed
Slide 11: SynCardia is Built to Scale: Here's Why
SynCardia is Built to Scale: Here's Why Leader in High - Demand Market We believe SynCardia is the leader in the total artificial heart market, addressing a global, multi - billion - dollar need where demand for donor hearts far exceeds supply Addresses Most Severe Patients Implantation with the STA
Slide 12: The Problem: Shortage of Donor Hearts Leaves Thousands Waiting
The Problem: Shortage of Donor Hearts Leaves Thousands Waiting Demand for Donor Hearts Exceeds Supply 1 7,500+ Patients Waiting on Heart Transplant List (yearly, 2012 to 2022) SynCardia's products are approved for sale in the U.S. and Canada only. SynCarida Systems, LLC is a wholly owned subsidiary
Slide 13: The Solution: The First FDA Approved Total Artificial Heart
The Solution: The First FDA Approved Total Artificial Heart — Designed for Hospital and Home Use The STAH is intended to replace a failing or failed human heart in patients with advanced stage heart failure and in need of a heart transplant The STAH is available in two sizes and comes with Hospital
Slide 14: Clinically Validated: Peer-Reviewed Outcomes Demonstrate STAH Survival Advantage
Survival Rate to transplantation (vs. 46% in control group) 1 79% Survival Rate at one year (vs. 31% in control group) 1 70% 75% Survival Rate at one year after heart transplant 2 SynCardia Total Artificial Heart Implants 3 Over 2,100 Over 7.5 Years Longest Living patient on the STAH 3 Clinically Va
Slide 15: Utilized by High Volume Transplant Centers Across the U.S. and Europe
Utilized by High Volume Transplant Centers Across the U.S. and Europe Centers of Excellence 1 High Volume U.S. and European Hospitals are Using SynCardia The First and Only Commercially Available Total Artificial Heart in the U.S. & Canada SynCardia's products are approved for sale in the U.S. and C
Slide 16: Lev'Veon's Story: Courage, Innovation, and a Lifesaving First
Lev’Veon’s Story: Courage, Innovation, and a Lifesaving First Age: 10 years old Diagnosis: Myocarditis Implanted: September 6, 2024 Transplanted: September 30, 2024 24 days of Support on the STAH Mott Children’s Hospital First STAH Implant Sources: Mott Children’s Hospital & SynCardia Systems, LLC S
Slide 17: From Implant to Advocacy: Empowering Lives with the STAH
From Implant to Advocacy: Empowering Lives with the STAH • Unique Beating Hearts is a compassionate non - profit organization headquartered in California. • Provides group counseling assistance and support to individuals who have undergone the surgical implantation of a Total Artificial Heart (TAH)
Slide 18: Near-Term Growth Drivers: Site Expansion, Education, Access and Reimbursement
Near - Term Growth Drivers: Site Expansion, Education, Enhancing Access and Reimbursement Protect existing transplant centers ; grow and acquire new centers Increase publications submissions, congress attendance Debunking common myths Secure new “Centers of Excellence” 1 Grow social media presence L
Slide 19: Mid-Term Growth Drivers: Label Expansion and Approvals
Mid - Term Growth Drivers: Label Expansion and Approvals Set to Fuel U.S. and Global Commercial Momentum Updated BTC Label (Expected 2Q26) Emperor Approval (Expected 2028) SynCardia's products are approved for sale in the U.S. and Canada only. SynCarida Systems, LLC is a wholly owned subsidiary of P
Slide 20: Long-Term Market Growth: Driven by R&D Pipeline and IP-Backed Innovation
Long - Term Market Growth: Driven by R&D Pipeline and IP - Backed Innovation 2H28 1H28 2H27 1H27 2H26 1H26 2H25 1H25 Platform / Product May Seek FDA Approval of Fully Implantable STAH (Emperor) May Seek FDA Approval of Next Generation Pneumatic Technology Driver (Unicorn) Patents Covering Next Gener
Slide 21: Decades of Clinical Leadership: SynCardia Outpaces Emerging Competitors
Decades of Clinical Leadership in BTT Patients: SynCardia’s Total Artificial Heart Outpaces Emerging Competitors BiVACOR® TAH Carmat Aeson® SynCardia Total Artificial Heart Not approved (US EFS in progress) Not approved (US EFS being restarted) Approved Regulatory Status (US & Canada) Not approved C
Slide 22: STAH Growth Trajectory: Regional Mix and Sales 2022–2024
STAH Growth Trajectory: Regional Mix and Sales 2022 – 2024 $0 $1 $2 $3 $4 $5 $6 - 5 10 15 20 25 30 2022 2024 STAH Sales (Units) by Region vs. Total Sales ($MM) 1 2022 to 2024 US & Canada 2023 Europe ROW (2) Net Sales SynCardia's products are approved for sale in the U.S. and Canada only. SynCarida S
Slide 23: Investment Drivers: Validated, Protected and Positioned for Growth
Investment Drivers: Validated, Protected and Positioned for Growth Leader in High - Demand Market Capturing Demand Where Transplants Fall Short Addresses Most Severe Patients Delivering Proven Outcomes in High - Risk Patient Populations Market Validation Clinically Proven with Scale and Longevity Co
Slide 24: SynCardia Systems, LLC – a Picard Medical Company
SynCardia Systems, LLC – a Picard Medical Company The STAH is approved for sale in the US and in Canada where it is indicated for use in cardiac transplant - eligible patients at risk of imminent death from biventricular failure. EU and international approvals are pending. For additional information